Eisai Innovation, Inc. — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
ProTgenprotgen.bioNov 2024
ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence.
BiotechHealthtechToronto
Juan Carlos Zuniga-Pflucker(Executive Officer, Director)
BoardFei Shen(Director)Ferdinand Massari(Director)
Co-investorsFACIT (Fight Against Cancer Innovation Trust)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.